Introduction
The Rho proteins are part of the ras superfamily that has .20 members and includes RhoA, RhoB, RhoC, Rac1 and cdc42. Rho proteins regulate actin dynamics, cell proliferation, apoptosis, survival, invasion and metastasis (1) (2) (3) (4) (5) (6) (7) . Although most Rho proteins support proliferation and malignant transformation, the protein RhoB is a tumor suppressor (1) (2) (3) (4) (5) 8) . Despite an 85% amino acid homology between RhoA, RhoB and RhoC, each of these proteins interacts with specific regulators and has preferential and distinct biological roles (9) .
RhoB is expressed at very low levels in 130 human cancer cell lines (10) . The expression of RhoB correlates significantly with tumor stage and proliferative index, as indicated by the loss of RhoB expression in 96% of invasive tumors and its 86% reduction in poorly differentiated tumors when compared with non-neoplastic epithelium (11) . RhoB prevents such oncogenes as EGFR, ErbB2, Ras and Akt from inducing tumor survival, malignant transformation, invasion and metastasis (12, 13) . Overexpression of RhoB inhibits oncogenic signaling in cultured human cancer cell lines and inhibits tumor growth in nude mice, resulting in apoptosis (14) .
Recently, the potential use of RhoB complementary DNA as a tumor suppressor gene in gene therapy has been investigated. The ectopic expression of RhoB in the lung cancer cell line A549 resulted in suppressed cell proliferation, anchorage-independent growth and xenograft tumor growth in nude mice (11) . RhoB has been restored through recombinant adenovirus transduction, which resulted in the apoptosis of the endogenous RhoB protein low-expressing cell lines OVCAR-3 and IGROV-1 via the activation of the intrinsic apoptotic caspase cascade (15) .
The mechanism of transcriptional regulation of RhoB has been reported. The RhoB promoter is associated with and repressed by histone deacetylase (HDAC) 1 and the induction of RhoB by HDAC inhibition was mediated by an inverted CCAAT box in the RhoB promoter (10) . Under genotoxic conditions, transcription of the RhoB gene is activated via interaction of activating transcription factor 2 (ATF-2) with the CCAAT-binding factor, NF-YA, at the inverted CCAAT box (16) . Farnesyltransferase inhibitors (FTIs) have been reported to induce RhoB expression via the inverted CCAAT box, which is mediated through epigenetic control involving HDAC1 dissociation, histone acetylase association and histone acetylation of the RhoB promoter (17) . Recently, the novel antitumor agent RS5444, which is in clinical trials for anaplastic thyroid cancer, has been found to bind peroxisome proliferator-activated receptor gamma, which transactivates RhoB expression and induces apoptosis (18) .
The expression of RhoB is critical for FTI-induced apoptosis in transformed murine embryo fibroblasts. The targeted deletion of the RhoB gene makes these cells resistant to FTI-induced apoptosis (19) . The protein diaphanous-related formin, a critical downstream player in RhoB-induced apoptosis, is also critical for the cell death mechanism engaged by FTI (20) . The interaction between RhoB and TNFAIP1 seems to be involved in apoptosis of NUGC-3 cells (21) . However, the mechanisms through which RhoB induces apoptosis as well as the downstream targets of RhoB are unclear.
We previously reported that NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells (22) . In the present study, we found that the upregulation of RhoB by NSC126188 is mediated via c-Jun N-terminal kinase (JNK) signaling. The transcriptional activation of RhoB via JNK-mediated signaling may involve a p300-binding site and the inverted CCAAT box, which differs from the FTIs that activate RhoB expression. Mouse monoclonal antibodies against RhoB and RhoC and rabbit polyclonal antibodies against RhoA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal antibodies against mitogen-activated protein kinase kinase (MKK) 4, p-MKK4(Ser257/Thr261), JNK, p-JNK(Thr183/Tyr185), c-Jun, p-c-Jun(Ser63), MKK7, p-MKK7(Ser271/Thr275), poly (ADP-ribose) polymerase, Caspasse-3, Bax, p21 and b-actin were supplied by Cell Signaling Technology (Danvers, MA). Mouse monoclonal antibodies against cyclin D1 antibody were obtained from BD Pharmingen (San Diego, CA). Cell culture NUGC-3 human gastric carcinoma line were maintained in a humidified incubator containing 5% CO 2 and cultured in RPMI 1640 medium containing 10% (vol/vol) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 lg/ ml streptomycin and 0.25 lg/ml amphotericin B at 37°C. The NUGC-3 cell line was obtained from the Cancer Bank and Pre-clinical Research Program at Korea Research Institute of Bioscience and Biotechnology (Daejeon, Korea).
Materials and methods

Western blot analysis
The cultured cells were harvested in RIPA buffer containing protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN; 1 tablet/50 ml buffer) and collected by gentle scraping. Whole cell lysates were analyzed by western blot analysis as described previously (23). Sulforhodamine B assay Growth inhibition of cancer cell lines in the presence of NSC126188 was determined using the Sulforhodamine B assay, as described previously (24) . The amount of Sulforhodamine B dye bound to the cell matrix was quantified using a spectrophotometer at 530 nm. Fifty percent growth inhibition (GI 50 ) values were determined by recording the concentration of NSC126188 required to inhibit 50% of total cell growth. Reverse transcription-polymerase chain reaction The mRNA levels of genes were measured by reverse transcription-polymerase chain reaction (RT-PCR), using methods described previously (25) . Total RNA was purified using a Qiagen RNeasy Mini kit (Qiagen; Hilden, Germany). RT-PCR was performed using an RNA template (1 lg/reaction) and specific primers as described in the One-step RT-PCR PreMix kit (iNtRON Biotechnology, Sungnam-si, Kyunggi-do, Korea). The primers used: 5#-GTGATTGTTGGTGATGGAGC-3# (RhoA forward), 5#-CTCGTGGC-CATCTCAAAAAC-3# (RhoA reverse), 5#-ATGTGCTTCTCGGTGGACAC-3# (RhoB forward), 5#-ATAGCACCTTGCAGCAGTTG-3# (RhoB reverse), 5#-AGTGGACCCCAGAGGTGAAG-3# (RhoC forward), 5#-CGAGTGGC-CATCTCAAACAC-3# (RhoC reverse), 5#-CAGATGGAGCTAGATCATGAA-3# (JNK1 forward), 5#-CATCTAACTGCTTGTCAGGGA-3# (JNK1 reverse), 5#-CATGGAGCTGGATCATGAAAG-3#
(JNK2 forward), 5#-TCTTCCAACTGGGCATCATAA-3# (JNK2 reverse), 5#-ATGGGGAAGGT-GAAGGTCGG-3# (GAPDH, Glyceraldehyde 3-phosphate dehydrogenase, forward) and 5#-CAGGAGGCATTGCTGATGAT-3# (GAPDH reverse).
Flow cytometric analysis NSC126188-treated or siRNA-transfected cells were harvested and stained by propidium iodide (PI) as described previously (26) . The populations of sub-G 1 cells were then analyzed by flow cytometry. The stained cells were analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA). Histograms were analyzed using Modifit software (Verity Software House, Topsham, ME).
Annexin V/PI double staining An Annexin V/PI double-staining analysis was performed as described by the manufacturer (BD Biosciences, Pharmingen, San Diego, CA). Cells were treated with NSC126188 for 12 h and washed twice with prechilled phosphatebuffered saline at 4°C. The treated cells were stained with the Annexin Vfluorescein isothiocyanate staining buffer and PI solution for 15 min at room temperature and then analyzed with a FACSCalibur flow cytometer (Becton Dickinson).
Knockdown of gene expression using siRNAs Knockdown of gene expression was performed using siRNAs according to methods described previously (21) . The following siRNAs were used: scrambled siRNA, 5#-CCUACGCCACCAAUUUCGUdTdT-3#; siRhoB1, 5#-CCGUCUUCGAGAACUAUGUdTdT-3#; siRhoC, 5#-GUCUACGUCCCUACUGUCUdTdT-3#; siMKK4, 5#-GGACAGAAGUGGAAAUAUdTdT-3#; siMKK7, 5#-GGAAGAGACCAAAGUAUAdTdT-3#; siJNK1, 5#-CGUGGAUUUAUGGUCUGUdTdT-3#; siJNK2, 5#-GACUCAACCUUCACUGUCdTdT-3# and sic-Jun, 5#-CAAGAAGAUGCGCCGCAAdTdT-3#. A total of 20-40 nM of each of these siRNAs was transfected into NUGC-3 cells according to the manufacturer's protocol. After a 24 h incubation period, the cells were treated with 3 lM NSC126188 and incubated for another 48 h. Finally, phenotypes and the knockdown of genes were analyzed by RT-PCR or western blot.
pGL2-RhoB promoter construction
A 595 bp DNA fragment (À185 to þ411) from the human RhoB promoter (17) was amplified by PCR using NCF7 genomic DNA as a template. The primers used for PCR amplification were 5#-ATTGGTACCGGCAGCGGCAGCAG-CAGCGCGG-3# (forward) and 5#-ATATAAGCTTAGCAGGAGGGGGCC-CGCGAACGC-3# (reverse). The series of 5#-deletion fragments of the RhoB promoter were generated using forward primer 5#-AATTGGTACC-GCTGCCTCTCCCAGCCC-3# (À152), 5#-ATTGGTACCCTGCAGGGGGC-GGCCAATCA-3# (À90), 5#-ATTGGTACCGCAGCGATGAGCTCAGCCGG-3# (À58) and 5#-ATTGGTACCGGCTATATTAAGAAAGTGGCCGG-3# (À21). The amplified DNA fragments were inserted into the RhoB KpnI/HindIII sites of pGL2-basic luciferase plasmid. 
Upregulation of RhoB induces apoptosis of NUGC-3 cells
Luciferase assay A luciferase assay was performed using a dual-luciferase reporter system (Promega, Madison, WI) as described previously (23). NUGC-3 cells at 70-80% confluence were transiently cotransfected with the pGL2-RhoB-luciferase plasmid containing the RhoB promoter and the pRL-SV40 gene encoding the firefly renilla luciferase and incubated for 24 h. Next, the cells were treated for 16 h with NSC126188 and samples were prepared. The firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay system. Luciferase activity was integrated over a 10 s period and measured using a luminometer (Victor X Light; Perkin Elmer, Waltham, MA). The results were normalized to the activity of renilla luciferase. For the inhibitor assay, cells were preincubated for 2 h with the inhibitor and treated for 16 h with NSC126188. All of the data represent means ± standard deviations from four independent experiments.
Results
Upregulation of RhoB-induced apoptosis of NUGC-3 cells treated with NSC126188 NSC126188, a piperazine alkyl derivative, induces apoptosis of HeLa cells by upregulating RhoB expression (22) . NSC126188 treatment of NUGC-3 cells, a human gastric cancer cell line, resulted in apoptosis, as demonstrated by Annexin-PI double-staining analysis (Figure 1 ). The early (16.41%) and late (11.96%) apoptotic cells increased after treatment of NUGC-3 cells with NSC126188. Microscopic observation showed clear growth inhibition of NUGC-3 cells by NSC126188 (Figure 1 ). The apoptotic cell death of NUGC-3 cells was verified by western blot analysis during treatment of cells with 5 lM of NSC126188 ( Figure 1C) , which indicated the activation of caspase 3, cleavage of poly (ADP-ribose) polymerase and increases in the expression of Bax, RhoB and p21.
Although RhoA, RhoB and RhoC share 85% amino acid sequence identity, they have distinct functions in cells (9) . Because upregulation of RhoB expression plays a crucial role in NSC126188-induced apoptosis in HeLa cells (22) , the effect of NSC126188 on the expression levels of RhoA and RhoC proteins were examined in the NSC126188-treated NUGC-3 cells. NSC126188 increased RhoB expression at both the messenger RNA and protein levels but did not increase RhoA and RhoC expression. Next, we asked whether siRNA knockdown of Rho proteins could affect NSC126188-induced apoptosis ( Figure 2B ). The knockdown of Rho proteins was confirmed by RT-PCR (supplementary Figure 2 is available at Carcinogenesis Online). In the absence of NSC126188, knockdown of Rho proteins did not significantly affect cell growth even though slight growth inhibition in RhoC-knockdown cells and morphological change in RhoAknockdown cells were observed. However, when cells were treated with NSC126188 and RhoB was knocked down by siRNA treatment, 55% of the cells were rescued from NSC126188-induced apoptosis. However, knockdown of either RhoA or RhoC did not affect NSC126188 treatment-induced apoptosis ( Figure 2B ). Analysis by flow cytometry found that RhoB knockdown significantly decreased apoptosis ( Figure 2C) , as indicated by the decrease in the sub-G 1 cells from 36.7 to 18.1% when cells were treated with NSC126188. The fragmentation of chromosomal DNA was also observed in scrambled siRNA-treated cells in the presence of NSC126188, but the knockdown of RhoB suppressed DNA fragmentation even when cells were treated with NSC126188 ( Figure 2D ). These results suggest that only RhoB plays a crucial role in NSC126188-induced apoptosis of NUGC-3 cells.
JNK inhibitor suppresses RhoB expression in NSC126188-induced apoptosis
To understand the mechanism involved in RhoB upregulation in NSC126188-induced apoptosis, we investigated the ability of various inhibitors to restore cell growth (Figure 3) . The compound SP600125, 
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a JNK1/2 inhibitor, rescued cells from growth inhibition by NSC126188, whereas both the reactive oxygen species (ROS) scavenger N-acetyl cysteine and the P38 mitogen-activated protein kinase (MAPK) inhibitor SB253580 did not. Microscopic observation showed similar results ( Figure 3A) . The relative survival in the presence of inhibitor also demonstrated that SP600125 suppressed NSC126188-induced apoptosis of NUGC-3 cells ( Figure 3B ). In the western blot analysis, SP600125 significantly reduced RhoB protein expression in the presence of NSC126188 compared with other inhibitors, which indicated that RhoB expression is correlated with apoptosis ( Figure 3C) . We determined the effect of inhibitors on activation of the RhoB promoter by a cell-based reporter assay that used plasmids containing the luciferase gene under RhoB promoter ( Figure 3D ). NSC126188 increased luciferase activity indicating an activation of the RhoB promoter in NUGC-3 cells. However, only SP600125 reduced luciferase activity, whereas the N-acetyl cysteine and p38 MAPK inhibitors did not. These results suggest that the JNK-mediated signaling may be involved in activation of RhoB expression in the presence of NSC126188.
JNK-mediated signaling is involved in upregulation of RhoB in the presence of NSC126188
The expression levels of proteins involved in JNK-mediated signaling were examined in cells treated with NSC126188 by western blot analysis ( Figure 4A ). The phosphorylation of both JNK1/2 and MKK4, which is upstream of JNK and p38 MAPK, occurred within 3 h and gradually increased during treatment with NSC126188. MKK7, another upstream activator of JNK, was also activated by NSC126188 within 3 h. The phosphorylation of JNK1/2 occurred at the same time. The transcription activator c-Jun, which is downstream of JNK, was phosphorylated ahead of the increase in RhoB expression. These results suggest that JNK signaling plays a major role in the upregulation of RhoB by NSC126188.
To confirm the involvement of JNK-mediated signaling in RhoB expression, the effects of the JNK inhibitor SP600125 on the expression of RhoB and other proteins in the presence of NSC126188 were examined in detail. Treatment with SP600125 decreased luciferase activity under the RhoB promoter in a dose-dependent manner ( Figure 4B ) and extensively suppressed both RhoB messenger RNA and protein expression ( Figure 4C ). The expression levels of both p-c-Jun and c-Jun significantly decreased, indicating the suppression of JNK activity. The ability of SP600125 to rescue cells from NSC126188-induced apoptosis was analyzed by flow cytometry, which demonstrated a reduction in the proportion of apoptosis-exhibiting sub-G 1 cells from 25.18 to 9.83% ( Figure 4D ). This result indicates that JNK-mediated signaling is associated with upregulation of RhoB in the presence of NSC126188.
Because activating the proteins involved in JNK-mediated signaling causes apoptosis, we also investigated the effect of knocking down these proteins in the presence of NSC126188 ( Figure 5 ). When MKK4 and MKK7 were knocked down with either siMKK4 or siMKK7, the expression of c-Jun and RhoB was downregulated. When JNK1 and JNK2 were knocked down with siJNK1 and siJNK2 (supplementary Figure 3 is available at Carcinogenesis Online), c-Jun was downregulated and RhoB expression was lowered ( Figure 5A ). When c-Jun was knocked down, RhoB was expressed at a basal level. To investigate the knockdown effect of proteins in the JNK signaling on RhoB transcription, RhoB-luciferase assays were carried out in the cells treated with various siRNA ( Figure 5B ). Control cells containing scrambled siRNA had luciferase activity that was dramatically increased, when NSC126188 was present. When cells were treated with siMKK4, siMKK7, siJNK1, siJNK2 or si-c-Jun, luciferase activity was reduced by approximately 40-50%, clearly demonstrating that NSC126188 increased RhoB expression via the JNK-mediated signaling pathway.
We next investigated if the knockdown of MKK4, MKK7, JNK1 or JNK2 rescues cells from apoptosis by measuring the relative survival of cells treated with the appropriate siRNA. Relative survival analysis ( Figure 5C ) and microscopic observation ( Figure 5D ) of cells with knockdowns of MKK4, MKK7, JNK1, JNK2 or c-Jun showed that the cells grew well even in the presence of NSC126188. This suggests that RhoB expression is at least regulated at the level of transcription via JNK signaling.
NSC126188 activated transcription of RhoB through p300-binding site via JNK-mediated signaling The FTIs have been reported to increase RhoB by generating ROS through dissociating HDAC1 and associating histone acetylase leading to histone acetylation of the RhoB promoter (16,17,27 ).
To investigate if FTIs transactivate the RhoB promoter using the mechanism associated with JNK-mediated signaling, we examined the effect of the JNK inhibitor SP600125 on RhoB expression in the presence of FTI-277 ( Figure 6A ). As expected, the presence of SP600125 reduced upregulation of RhoB by NSC126188. However, FTI increased RhoB expression without increasing phosphorylation of c-Jun. Furthermore, SP600125 did suppressed p-c-Jun regardless of RhoB expression, indicating RhoB expression by FTI is not regulated by JNK-mediated signaling.
Reporter assays of various RhoB promoter constructs were used to elucidate the crucial regions to regulate RhoB expression ( Figure 6B ). When the construct À185 that contained the p300-binding site and two CCAAT boxes, including inverted CCAAT sequence (iCCAAT box), was treated with NSC126188, RhoB promoter activity increased 10-to 13-fold ( Figure 6C ). However, construct À152, which deleted 33 bp at the 5# flanking region, construct À90 and construct À58 all significantly reduced RhoB promoter activity, suggesting that the region containing the p300-binding site has a crucial role in the regulation of the NSC126188-induced RhoB promoter activity. Also, the importance of the inverted CCAAT sequence in the construct-58 was demonstrated by the reduced RhoB promoter activity in the construct-21 that deleted the iCCAAT box.
The NSC126188-induced RhoB promoter activity in the construct-185 was inhibited by SP600125, suggesting that the region containing the p300-binding site may be regulated by JNK-mediated signaling. The iCCAAT box may also be regulated by JNK-mediated signaling, but that is not clear until direct binding assay of c-Jun and p300 at the The reporter assay using various RhoB promoter constructs in the presence of NSC126188. NUGC-3 cells were cotransfected for 24 h with both the pGL2-RhoB constructs and the renilla luciferase plasmids, then incubated for 2 h with SP600125 and then treated for 16 h with either 5 lM NSC126188. Luciferase activity was measured using dual-luciferase assay kit (Promega). Transfection efficiency was normalized to the activity of the renilla luciferase. All data represent means ± standard deviations from four independent experiments. (D) The reporter assay using various RhoB promoter constructs in the presence of FTI-277. NUGC-3 cells were co-transfected for 24 h with both the pGL2-RhoB constructs and the renilla-luciferase plasmids, then incubated for 2 h with SP600125, and then treated for 16 h with 10 lM FTI-277.
Upregulation of RhoB induces apoptosis of NUGC-3 cells p300-binding site can be assayed with oligonucleotides containing a mutated p300-binding site.
The effects of FTI-277 on luciferase reporter assays were examined by various RhoB promoter constructs ( Figure 6D ). FTI-277 increased RhoB promoter activity $5-to 8-fold, when assayed with construct À185, À152, À90 or À58, but not with construct-21. The construct deleting the region containing the p300-binding site did not decrease RhoB promoter activity. The construct-21, which deleted the iCCAAT box, substantially reduced luciferase activity, implying that the inverted CCAAT is involved in activating the RhoB promoter by FTI and consistent with the report that FTI activates RhoB expression via an inverted CCAAT box (16, 28) . Furthermore, the transactivation of RhoB by FTI-277 was not suppressed by the JNK inhibitor, which suggests that increased RhoB expression in the presence of FTIs is not associated with JNK signaling, which is a different result than that obtained with NSC126188.
Overall, NSC126188 increased RhoB transcription via JNK-mediated signaling, presumably through the p300-binding site and the inverted CCAAT box. The transcriptional activation of RhoB by NSC126188 is different from its activation by FTIs.
Discussion
Rho proteins were first described as playing an important role in the morphological responses of cells to extracellular stimuli. Recently, RhoB, a tumor suppressor, has become an interesting target in cancer therapeutics for its pro-apototic function (11, 15, 18) . Here, we examined the ability of NSC126188-upregulated RhoB expression via JNK signaling to induce apoptosis of NUGC-3 gastric cancer cells and found that NSC126188 affects the expression of only RhoB and not of RhoA or RhoC.
The expression of RhoB has been found to be increased by stimuli including radiation, growth factors, cytokines and genotoxic stress (29) . We have reported that the transient expression of RhoB caused apoptosis of NUGC-3 cells via JNK-mediated signaling (21) . FTIs increase the ROS-mediated expression of RhoB through dissociating HDAC1 and associating histone acetylase, which leads to histone acetylation of the RhoB promoter (17) . The transcriptional activation of the RhoB gene via a CCAAT box in a genotoxic condition was shown in the involvement of activating transcription factor 2 (ATF-2) with NF-YA, the CCAAT-binding factor (16, 28) . However, the involvement of FTI in the signal transduction pathways of JNK, extracellular signal-regulated kinase and p38 MAPK that induce RhoB has not been well studied (13) .
ROS scavenger did not affect NSC126188-induced apoptosis, suggesting that ROS are not particularly relevant to NSC126188-induced apoptosis of NUGC cells. Since a p38 inhibitor did not rescue cell growth or suppress activation of the RhoB promoter in the presence of NSC126188, p38 signaling is unlikely to be involved in RhoB expression. Apoptosis induced by NSC126188 seems to be p53 independent because RhoB expression was stimulated in both HCT-116 p53 þ/þ and HCT-116 p53 À/À cells (data not shown).
The JNK inhibitor SP600125 suppressed both NSC126188-induced apoptosis and RhoB expression at the level of transcription in NUGC-3 cells. JNKs, a subfamily of MAPK, are involved in numerous physiological or pathological processes that include proliferation, differentiation and cell death. JNK1 and JNK2 are ubiquitously expressed in most tissues, whereas JNK3 is expressed selectively in the nervous system and displays low levels of expression in the heart and testis. The ability of SP600125 to inhibit c-Jun phosphorylation suggests that RhoB expression is regulated by JNK signaling in the NSC126188-induced apoptosis of NUGC-3 cells. Knockdown by siRNA of proteins in JNK-mediated signaling decreased in RhoB expression and restored cell growth even in the presence of NSC126188. A reporter assay using various RhoB promoter constructs in the presence of NSC126188 found that SP600125 suppressed NSC126188-induced RhoB promoter activity. The region containing the p300-binding site and the iCCAAT box played crucial roles for the NSC126188-induced RhoB promoter activity. These results suggest that the JNK-mediated pathway involves upregulation of RhoB, which contributes to the apoptotic response to NSC126188 by NUGC-3 cells. However, the effect of FTIs on the activation of the RhoB promoter may not be associated with JNKmediated signaling. The detailed mechanism of transcriptional activation of RhoB by NSC126188 is under investigation.
The transcriptional coactivator protein p300 acts as a key player in cellular differentiation and growth control. It also coordinates and integrates multiple signal-dependent processes at the transcriptional level (30) . The simultaneous interaction of multiple transcription factors, including c-Jun with p300, may contribute to the transcriptional activation of RhoB through binding to the p300-binding site and the iCCAAT box. Systematic experiments are planned to elucidate the functions of the p300-binding site and the iCCAAT box in the transcription of RhoB. The RhoB inducing antitumor agent RS5444 binds to the transcriptional factor peroxisome proliferatoractivated receptor gamma to turn on the RhoB tumor suppressor gene. Future work should examine the possible role of peroxisome proliferator-activated receptor gamma in NSC126188-induced apoptosis.
In conclusion, we have demonstrated that RhoB-triggered apoptosis may serve as a key mechanism of the anticancer agent NSC126188. NSC126188 activates RhoB expression via JNKmediated signaling, which has no effect on the FTI-induced RhoB promoter activity. Supplementary Figures 1-3 can be found at http://carcin.oxfordjournals.org/ 
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